AbL Diagnostics SA

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions for molecular detection by polymerase chain reaction (PCR) and DNA sequencing in France and internationally. Its offerings include genotyping by NGS and Sanger sequencing for HIV, SARS-CoV-2, hepatitis C, Mycobacterium tuberculosis, 16S/18S RNA, hepatitis B (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK virus (BKV), human papillomavirus (HPV), respiratory syncytial virus (RSV), and Salmonella, as well as real-time PCR assays and ultragene assays for viral detection of SARS-CoV-2, monkeypox, and Clostridium. The company also supplies microbiological specimen transport and collection kits, instruments and consumables such as DNA/RNA extraction systems, real-time PCR systems, liquid handling robots, NGS library preparation kits, and Sanger sequencing reagents, along with digital solutions including analysis software, data hosting, lab automation, Nadis, and SeqHepB. It sells directly and through distributors to academic clinical pathology labs, private reference labs, and researchers. Formerly known as Etablissements Fauvet Girel, it changed its name to ABL Diagnostics Société anonyme in April 2022, is headquartered in Woippy, France, and is a subsidiary of Advanced Biological Laboratories (ABL) S.A.